Darovasertib and Crizotinib for HLA-A2-Negative Metastatic Uveal

Darovasertib and Crizotinib for HLA-A2-Negative Metastatic Uveal Melanoma
47%36%25%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 21 • YES 42.3%May 22 • YES 35.9%May 23 • YES 42.3%May 24 • YES 33.9%May 26 • YES 30.2%May 27 • YES 42.0%
IDEAYA Biosciences ($IDYA)
No stock close$29.86$28.99$28.11May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 18 • IDYA $28.32May 19 • IDYA $28.32May 20 • IDYA $29.65May 21 • IDYA $29.54May 22 • IDYA $29.10May 26 • IDYA $29.35May 27 • IDYA $29.28

Will this trial show a positive result on overall survival in Phase 3?

Paper Trading
Create account to trade
ClinicalNewsTrialPositionsReasoningOracle
Scientific editorial illustration for HLA-A2-Negative Metastatic Uveal Melanoma

HLA-A2-Negative Metastatic Uveal Melanoma

Uveal melanoma is a rare eye cancer that can spread, most often to the liver. Human leukocyte antigen A2 negative disease lacks a treatment-matching marker, so survival matters because living longer matters.

1U.S. incidence: ~4.3 per million people yearly2Liver involvement: >90% of metastatic cases3Distant-stage survival: 19% 5-year relative survival